Comprehensive evaluation of liver microsomal cytochrome P450 3A (CYP3A) inhibition: comparison of cynomolgus monkey and human

1. Members of the cytochrome P450 3A (CYP3A) subfamily metabolize numerous compounds and serve as the loci of drug-drug interactions (DDIs). Because of high amino acid sequence identity with human CYP3A, the cynomolgus monkey has been proposed as a model species to support DDI risk assessment. 2. Th...

Full description

Saved in:
Bibliographic Details
Published in:Xenobiotica 2017-06, Vol.47 (6), p.470-478
Main Authors: Haarhoff, Zuzana E., Kramer, Melissa A., Zvyaga, Tatyana A., Zhang, Jun, Bhutani, Priyadeep, Subramanian, Murali, Rodrigues, A. David
Format: Article
Language:English
Subjects:
Animals
Cynomolgus monkey
CYP3A
Cytochrome P-450 CYP3A - metabolism
Cytochrome P-450 CYP3A Inhibitors - metabolism
Cytochrome P-450 CYP3A Inhibitors - pharmacology
DDI model
Diltiazem
Drug Interactions
drug-drug interaction
Humans
in vitro-in vivo extrapolation
Kinetics
Macaca fascicularis
Microsomes, Liver - metabolism
Midazolam - metabolism
Midazolam - pharmacology
Models, Biological
time-dependent inhibition
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:1. Members of the cytochrome P450 3A (CYP3A) subfamily metabolize numerous compounds and serve as the loci of drug-drug interactions (DDIs). Because of high amino acid sequence identity with human CYP3A, the cynomolgus monkey has been proposed as a model species to support DDI risk assessment. 2. Therefore, the objective of this study was to evaluate 35 known inhibitors of human CYP3A using human (HLM) and cynomolgus monkey (CLM) liver microsomes. Midazolam was employed as substrate to generate IC 50 values (concentration of inhibitor rendering 50% inhibition) in the absence and presence of a preincubation (30 mins) with NADPH. 3. In the absence of preincubation, the IC 50 values generated with CLM were similar to those obtained with HLM (86% within 2-fold; 100% within 3-fold difference). However, significant differences (up to 48-fold) in preincubation IC 50 were observed with 17% of the compounds (raloxifene, bergamottin, nicardipine, mibefradil, ritonavir, and diltiazem). 4. Our results indicate that in most cases the cynomolgus monkey can be a viable DDI model. However, significant species differences in time-dependent CYP3A inhibition can be observed for some compounds. In the case of raloxifene, such a difference can be ascribed to a specific CYP3A4 amino acid residue.
ISSN:0049-8254
1366-5928
DOI:10.1080/00498254.2016.1203042